Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis

• Published in: European journal of clinical pharmacology Vol. 77; no. 11; pp. 1597 - 1609
• Main Authors: Hsu, Yu-Chen, Chen, Ching-Yao, Tam, Ka-Wai, Hsu, Chin-Yu
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2021; Springer Nature B.V
• Subjects: Antiemetics - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Biomedical and Life Sciences; Biomedicine; Chemotherapy; Clinical trials; Constipation; Granisetron - adverse effects; Granisetron - therapeutic use; Headache; Humans; Meta-analysis; Nausea; Nausea - chemically induced; Nausea - drug therapy; Palonosetron - adverse effects; Palonosetron - therapeutic use; Pharmacology/Toxicology; Quality of Life; Randomized Controlled Trials as Topic; Review; Serotonin; Serotonin 5-HT3 Receptor Antagonists - therapeutic use; Vomiting; Vomiting - chemically induced; Vomiting - drug therapy; Chemotherapy; Granisetron; Nausea; Vomiting; Palonosetron; Meta-analysis
• ISSN: 0031-6970; 1432-1041
• DOI: 10.1007/s00228-021-03157-2

Purpose Chemotherapy-induced nausea and vomiting (CINV) commonly occurs after chemotherapy, adversely affecting patients’ quality of life. Recently, studies have shown inconsistent antiemetic effects of two common 5-hydroxytryptamine 3 receptor antagonists, namely, palonosetron and granisetron. Therefore, we conducted a meta-analysis to evaluate the effectiveness of palonosetron versus granisetron in preventing CINV. Methods Relevant studies were obtained from PubMed, Embase, and Cochrane databases. The primary outcome was the complete response (CR) rate. Secondary outcomes were headache and constipation events. Results In total, 12 randomized controlled trials and five retrospective studies were reviewed. Palonosetron was consistently statistically superior to granisetron in all phases in terms of the CR rate (acute phases: odds ratio [OR] = 1.28, 95% confidence interval [CI] = 1.06–1.54; delayed phases: OR = 1.38, 95% CI = 1.13–1.69; and overall phases: OR = 1.37, 95% CI = 1.17–1.60). Moreover, a non-significant difference was found between the two groups in terms of the headache event, but the occurrence of the constipation event was lower in the granisetron group than in the palonosetron group. Conclusion Palonosetron showed a higher protective efficacy in all phases of CINV prevention, especially in delayed phases, and no relatively severe adverse effects were observed.